One such commonly used medication for dermatologic and rheumatologic inflammatory conditions is hydroxychloroquine (Plaquenil), a chloroquine derivative. It is used to treat many diseases including malaria, rheumatoid arthritis and systemic lupus erythematosus. Maculopathy plaquenil Structure activity relationship of chloroquine ppt Our results show that the prevalence of hydroxychloroquine retinopathy is much higher than previously recognized and depends on risk factors such as daily dose, duration of use, and kidney disease. The results also suggest the need to revise the way that dosage is calculated to minimize risk. In addition, toxic maculopathy has been reported to be dose dependent, whereby retinal toxicity risk increases with more than 6.5mg/kg of body weight. 6. Other risk factors include advanced age and pre-existing retinal disease. Patients with any of the aforementioned findings are considered “high risk” and should be monitored closely. Melles R, Marmor M. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132121453-60. 6. Michaelides M, Niam H, Stover P, et al. Retinal toxicity associated with hydroxychloroquine and chloroquine risk factors, screening, and progression despite cessation of therapy. It is imperative that patients and physicians are aware of and watch for this drug’s ocular side effects. Retinal toxicity from hydroxychloroquine is rare, but even if the medication is discontinued, vision loss may be irreversible and may continue to progress. Plaquenil retinopathy risk factors The Risk of Retinal Toxicity with Plaquenil - Sjogren's, New Plaquenil Guidelines Chloroquine phosphate tablets side effectsPlaquenil and accutane A cookie-cutter approach to dosing Plaquenil hydroxychloroquine, Sanofi-Aventis, an anti-malarial drug that has been used as a treatment for systemic lupus erythematosus and rheumatoid arthritis. Despite Plaquenil dosing recommendations, retinal toxicity.. How to Succeed in Plaquenil Screenings. Hydroxychloroquine retinopathy screening. Plaquenil hydroxycholoroquine is a medication used to treat lupus, rheumatoid arthritis and other inflammatory and dermatologic conditions. It is very effective and the risk of damage to the eye is very low the first five years if the patient is receiving the recommended dose and does not have special risk factors like kidney damage. A risk factor for Plaquenil hydroxychloroquine retinotoxicity is a daily dose that exceeds 5.0 mg of drug per kg of body weight. The tool on the right simply calculates this threshold based on a ppatient’s real body weight. It’s important to understand that the daily dose is only one risk factor for plaquenil retinotoxicity. The risk may be much higher because retinopathy can be detected earlier when using more sensitive screening techniques. OBJECTIVES To reassess the prevalence of and risk factors for hydroxychloroquine retinal toxicity and to determine dosage levels that facilitate safe use of the drug.